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PURPOSE. To establish the identity of a prominent protein,
approximately 70 kDa, that is markedly increased in the retina
of monkeys with experimental glaucoma compared with the
fellow control retina, the relationship to glaucoma severity,
and its localization in the retina.
METHODS. Retinal extracts were subjected to 2-D gel electro-
phoresis to identify differentially expressed proteins. Purified
peptides from the abundant 70 kDa protein were analyzed and
identified by liquid chromatography/mass spectrometry/mass
spectrometry (LC/MS/MS) separation, and collision-induced
dissociation sequencing. Protein identity was performed on
MASCOT (Matrix Science, Boston, MA) and confirmed by West-
ern blot. The relationship between the increase in this protein
and glaucoma severity was investigated by regression analyses.
Protein localization in retina was evaluated by immunohisto-
chemistry with confocal imaging.
RESULTS. The abundant protein was identified as Macaca mu-
latta serum albumin precursor (67 kDa) from eight non-over-
lapping proteolytic fragments, and the identity was confirmed
by Western blot. The average increase in retinal albumin con-
tent was 2.3 fold (P  0.015). In glaucoma eyes, albumin was
localized to some neurons of the inner nuclear layer, in the
inner plexiform layer, and along the vitreal surface, but it was
only found in blood vessels in control retinas.
CONCLUSIONS. Albumin is the abundant protein found in the
glaucomatous monkey retinas. The increased albumin is pri-
marily localized to the inner retina where oxidative damage
associated with experimental glaucoma is known to be prom-
inent. Since albumin is a major antioxidant, the increase of
albumin in the retinas of eyes with experimental glaucoma may
serve to protect the retina against oxidative damage. (Invest
Ophthalmol Vis Sci. 2010;51:952–959) DOI:10.1167/iovs.09-
4331
Glaucoma is a leading cause of blindness worldwide affect-ing over 67 million people.1 Primary open-angle glaucoma
(POAG) is the most common form of the disease and accounts
for 90% of glaucoma patients. This form of the disease is
generally insidious in origin, bilateral, and progresses slowly
with visual symptoms occurring primarily in late stages of the
disease. Normal intraocular pressure (IOP) ranges from 8 to 21
mm Hg, and individuals with IOP higher than 21 mm Hg are
considered to be at risk for developing glaucoma. However,
some patients with abnormally high IOP never develop visual
deficits, while some patients with visual field loss characteristic
of glaucoma do not have abnormally high pressures. In some
families, the disorder appears to be genetically determined,2
but some of the mutations found associated with POAG show
ethnic bias.3–5
Several hypotheses have been proposed for potential mech-
anisms triggering retinal ganglion cell injury and death in glau-
coma. Mechanisms that have been proposed include compro-
mise to blood flow at the optic nerve,6,7 mechanical
compression,8 loss of neurotrophic factors and TrkB receptor
alterations,9,10 autoimmune mechanisms,11–13 nitric oxide–in-
duced injury to the optic nerve,14–16 and glutamate excitotox-
icity.17–19 In addition to these primary mechanisms, a number
of studies have provided evidence that oxidative stress and
damage contribute to degeneration of retinal ganglion cells in
glaucoma.20 Oxidative changes have been reported in the
retinas of animals with experimentally induced glaucoma, in-
cluding a decrease in endogenous antioxidant enzyme activity,
an increase in lipid peroxidation21 and protein oxidation,22
and an up-regulation of iron regulatory proteins that have
antioxidant properties.23 These oxidative alterations in glau-
coma may contribute directly to ganglion cell damage and
death, or trigger downstream effectors,20 and can be initiated
by many of the mechanisms of glaucomatous neuropathy that
have been proposed. Although much is known about the
pathologic changes in glaucoma retinas, the precise mecha-
nisms contributing to the injury and death of retinal ganglion
cells (RGCs) are not fully understood.
Regardless of the precise mechanisms, gene regulation and
expression must be altered in the retinas of glaucomatous eyes
compared with normal retinas. Changes may occur at tran-
scriptional, translational, or post-translational levels and can
occur as a result of RGC cell death or as a result of protective
responses of the retinal cells to the adverse stress. Identifica-
tion and characterization of proteins that are either up- or
downregulated in the glaucomatous eye may provide impor-
tant insights into the mechanisms contributing to RGC death.
In the present investigations of protein levels in the monkey
retinas of control eyes and eyes with experimental glaucoma,
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elevated levels of a protein with a molecular weight of approx-
imately 70 kDa was found in the glaucoma retinas. The protein
was isolated by 2-D gel electrophoresis, analyzed by liquid
chromatography/mass spectrometry/mass spectrometry (LC/
MS/MS), and revealed to be albumin. The prevalence and
magnitude of the increase in albumin, after the induction of
experimental glaucoma, were determined, as well as the rela-
tionship to the severity of glaucoma and the retinal localization
in glaucomatous eyes.
MATERIALS AND METHODS
Animals
Seven rhesus monkeys (Macaca mulatta) ranging in age from 7 to 11
years of age (six males and one female, ocular hypertensive [OHT]-40)
were subjects for the study. The high intraocular pressure (IOP) model
of experimental glaucoma was created by laser scarification in the
drainage angle to restrict the outflow of aqueous humor from the
anterior chamber and, thereby, elevate the IOP.24 Typically, several
laser treatments, separated by at least four weeks, were required to
create sustained IOP levels and initiate an optic neuropathy. The
effects of experimental glaucoma were assessed over periods of 2 to 14
months after elevated IOP by behavioral methods using standard au-
tomated perimetry (SAP; Humphrey Field Analyzer; Carl Zeiss Meditec,
Inc., Jena, Germany) for monkeys that had been trained to perform a
psychophysical detection task.25,26 With well-trained subjects, behav-
ioral SAP produced visual field data for monkeys in the same format as
the standard clinical data for humans. The stage of glaucomatous
neuropathy was based on the visual fields because of the prior studies
that showed a poor relationship between visual field defects and the
level or duration of experimental glaucoma,27 but a high correlation
between visual field defects and the density of RGCs.28
Male Wistar rats weighing 350 g–450 g were anesthetized with a
mixture of ketamine (50 mg/kg), acepromazine (1 mg/kg), and xyla-
zine (5 mg/kg). IOP was elevated by laser photocoagulations (blue-
green argon laser; Coherent, Palo Alto, CA) of episcleral veins approx-
imately 50 m in diameter (1 watt for 0.2 seconds) within 0.5 mm–0.8
mm from the limbus and on the veins around the limbus as described
previously.29 IOP was measured (TONO-PEN; Mentor, Norwell, MA30)
on rats calmed with acepromazine, 3.0 mg/kg intramuscularly, and
proparacaine (0.5%; Opthetic; Allergan, Irvine, CA) applied topically
on the eyes to anesthetize the cornea. The average of 15 readings for
each eye was taken as the IOP for that eye. Three rats were donated for
the study with average control IOP of 15.08  0.0949 ( SD) mm Hg
and elevated IOP of 31  2.035 mm Hg for two weeks. All procedures
were conducted in accordance with approved procedures by the
Institutional Animal Care and Use Committees at The University of
Houston, The University of Texas Health Science Center at Houston
and Allergan, Inc., and with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research.
Tissue Preparation
Eyes were removed from deeply anesthetized monkeys and a sample of
retina taken by a 5-mm dermal biopsy punch beginning 20° from the
fovea and extending peripherally to 40° from the temporal inferior
retina in each eye. The retina was detached from the pigment epithe-
lium, placed in small conical tubes, quickly frozen in liquid nitrogen
and stored at –80°C. The remaining eyecups were fixed in 4% para-
formaldehyde (0.1 M phosphate buffer; pH 7.4).
One-D and Two-D Gel Electrophoresis
To generate cytosolic protein preparations, frozen monkey retinas
were ultra-sonicated 10 seconds in lysis buffer (50 mM Tris-HCl [pH
7.4], 150 mM NaCl, 0.5% NP-40) with 2% protease inhibitors cocktail
(Sigma Aldrich, St. Louis, MO), incubated on ice for 30 minutes, and
centrifuged at 14,000 rpm for 15 minutes at 4°C. Protein concentration
was determined using a bicinchoninic acid protein assay kit (BCA
Protein Assay Kit; Pierce, Rockford, IL) with bovine serum albumin
(BSA) as the reference standard. For 1-D gel analysis, 20 g protein was
diluted in an equal volume of 2X Laemmli buffer (125 mM Tris-HCl [pH
6.8], 4% SDS, 20% glycerol, and 200 mM -mercaptoethanol), and the
samples were boiled for five minutes. After centrifugation, the super-
natant was separated on a 15% SDS-PAGE. For 2-D analysis, 20 g
protein was dialyzed against 7 M urea (3.5k MWCO; Pierce Biotech-
nology, Rockford, IL) for 1.5 hours at room temperature. The retentate
was diluted in sample buffer containing 7 M urea, 2 M thiourea, 2%
CHAPS, and 65 mM DTT, and 15 g protein was loaded by passive
rehydration onto 7-cm strips (Immobiline DryStrips, pH 3–11NL; GE
Healthcare, Piscataway, NJ) overnight at room temperature. For the
first dimension separation, isoelectric focusing (IEF) was performed at
15°C using a maximum 50 mA/strip current. The IEF program con-
sisted of: 450 V/hr at 300 V, 325 V/hr ramped to 1000 V, 500 V/hr at
1000 V, 1250 V/hr at 5000V, and 583 V/hr at 7000 V. For the second
dimension, IEF strips were equilibrated in buffer containing 50 mM
Tris-HCl (pH 6.8), 6 M urea, 30% glycerol, 2% SDS, and 65 mM DTT,
followed by the same buffer containing 2.5% iodoacetamide, then
separated on a 12% acrylamide gel by SDS-PAGE.31
Total protein was stained (Deep Purple; GE Healthcare) following
the manufacturer’s suggested protocol, and images of the proteins
pattern were scanned (Molecular Imager FX and Quantity One soft-
ware; Bio-Rad, Hercules, CA). For mass spectrometry identification,
gels were restained (Coomassie Colloidal Blue; Invitrogen, Carlsbad,
CA) according to the suggested protocol, and the desired spots ex-
cised. The gel punches (see Fig. 2) were destained for 15 minutes in
30% ethanol, re-equilibrated with water, and analyzed by LC/MS/MS as
described below.
Protein Identification
Proteins were identified in the Proteomics Core Facility at the Univer-
sity of Texas Health Science Center at Houston. Analysis was per-
formed using LC/MS/MS (QStar XL; Applied Biosystems, Foster City,
CA) equipped with an LC Packings high-performance liquid chroma-
tography (HPLC) for capillary chromatography. Direct analysis of the
eluate was made by HPLC coupled to the mass spectrometer by a
nanospray ESI (Electrospray Ionization) head. For protein identifica-
tion, spots of interest were excised from the gel with a clean glass
pipette and subjected to in-gel proteolytic digestion with trypsin es-
sentially as described previously.32 After extraction of the peptides, an
aliquot was separated by HPLC on a C18 75 m x 10 cm reversed-phase
capillary column (Vydac 218MS3.07510; Grace, Deerfield, IL). The
column was developed with a gradient of 2% to 50% acetonitrile in
0.1% formic acid over 30 minutes at a flow rate of 200 nL/min. The
nanospray source, fitted with a 30-m coated tapered fused silica tip
(New Objective, Cambridge, MA), was used to elute the peptides
directly into the mass spectrometer for tandem mass spectrometry
(MS/MS) analysis. The LC/MS/MS instrument (QStar XL; Applied Bio-
systems) was operated in Information Dependent Acquisition mode
using a one second survey scan followed by two consecutive three
second product ion scans of 2, 3, and 4 parent ions (m/z 350-
1500). Identification was performed using the MASCOT (Matrix Sci-
ence, Boston, MA) search engine (Matrixscience.com) with an MS and
MS/MS mass tolerance of 0.15 Da.
Western Blot Analysis
Fifteen g of retinal protein extract from the control and the glaucoma
retinas were loaded on 8% gels in neighboring lanes for each of seven
monkeys, separated by SDS-PAGE, and transferred to a nitrocellulose
membrane. The membranes were blocked with 5% nonfat milk in TBST
buffer (10 mM Tris, 154 mM NaCl [pH 7.4], 0.05% Tween-20) and
incubated overnight at 4°C with a monoclonal anti-albumin antibody
(A6684;1:20,000; Sigma Aldrich) in the blocking buffer. Membranes
were washed in TBST and exposed to a peroxidase-conjugated goat
anti-mouse secondary antibody (Pierce, Rockford, IL) diluted 1:50,000
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in blocking buffer for one hour at room temperature. The membranes
were washed and immunoreactive bands visualized by pico luminol/
enhancer solution (SuperSignal West; Pierce). The blots were stripped
and reprobed with monoclonal anti--actin antibody (A5441, 1:50,000;
Sigma Aldrich) to normalize data for differences in quantity of protein
loaded.
Immunohistochemistry
Samples of monkey retina, one millimeter in diameter (contiguous with
that for biochemical analysis), were taken from temporal retina be-
tween 40° and 45° from the fovea of control and glaucoma eyes and
embedded in ultra-low gelling temperature agarose (Sigma-Aldrich).
Sections of retina were cut at a thickness of 40 m on a vibratome
(Vibratome 1000 Plus Sectioning System; Technical Products Interna-
tional, Inc., St. Louis, MO), and blocked in a solution containing 3%
normal goat serum, 0.3% Triton X-100, and 0.1% sodium azide in PBS
for three hours at room temperature. The sections were exposed to the
same monoclonal anti-albumin antibody used for the Western blot
analysis (1:1000) diluted in 1% normal goat serum, 0.3% Triton X-100,
0.1% sodium azide in PBS for three hours at room temperature. All
sections were washed with 1% normal goat serum, 0.3% Triton X-100,
and 0.1% sodium azide in PBS for 6  30 minutes, and then incubated
with Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA). The nuclei were stained with DAPI
(4-6-diamidino-2-phenylindole), a DNA stain. Images of retina from
control and experimental retinas were taken using identical parame-
ters with a confocal microscope (LSM 510; Carl Zeiss Inc., Jena,
Germany).
RESULTS
Differential Expression Pattern of
Retinal Proteins
The expression pattern of retinal proteins in eyes with exper-
imental glaucoma differed from that of control eyes. Retinal
proteins separated by SDS-PAGE and stained with the fluores-
cent protein dye revealed an apparent increase in protein in a
band near 70 kDa, and apparent decreased protein content in
several protein bands, in samples from eyes with experimental
glaucoma compared to that of control eyes (Fig. 1). The in-
crease in protein abundance near 70 kDa was a robust and
consistent finding and was chosen for further investigation to
identify proteins(s) whose relative abundance is increased after
the induction of experimental glaucoma.
Identity of the Abundant Protein Near 70 kDa
The protein band near 70 kDa may contain several proteins,
therefore further protein separation by 2-D gel was conducted
and spots containing the abundant protein near 70 kDa were
removed for analysis by mass spectrometry (Fig. 2). In-gel
proteolytic digestion of the excised spots with trypsin recov-
ered eight peptides. MS/MS collision-induced dissociation was
used to establish the amino acid sequences of eight peptides
generated from the trypsin proteolytic digestion. MASCOT
search results using the peptide masses and amino acid se-
quences positively identified the protein as serum albumin
(predicted MW-67,837 Da, pl-5.85). As shown in Figure 3A,
eight non-overlapping peptides (shown in bold) gave over 15%
sequence coverage, and the predicted molecular weight and
isoelectric point is in agreement with the spot migrations (Fig.
2). Identity or extensive homology is indicated for peptides
with ion scores  42 (P  0.05). Ions scores for the eight
tryptic peptides identifying albumin ranged from 46 to 65. The
MS/MS spectrum for a representative peptide is shown in
Figure 3B.
To confirm the protein identity as albumin, Western blot
analysis was conducted on equal amounts of retinal protein
extracts from control and glaucomatous retinas. A prominent
single band for albumin was detected in all lanes near 70 kDa,
when the membrane was probed with an antibody directed
against human albumin (antibody specificity determined be-
fore use). This positive labeling with the antibody to human
albumin confirmed the identity of the abundant protein as
albumin (Fig. 4A).
To quantitatively analyze the increase in albumin in the
glaucomatous retina, the mean ratio in immunolabeling density
for albumin between the two eyes of each monkey was com-
pared, after normalizing the density of the albumin band to that
of -actin in the same lane. To control for possible variation
between monkeys, the non-lasered eye (control) was com-
pared with the laser-treated glaucomatous eye of the same
monkey. The paired t-test was performed to see if the differ-
ence in albumin expression between the control and experi-
mental retinas is significant. This analysis revealed that the
average increase of albumin was 2.3-fold in the glaucoma
retinas (Fig. 4B; log-transformed paired t-test; P 0.0150; SE of
ratio  1.28) versus the matched control retinas. These results
clearly indicate that an increase in albumin may be a common
feature of glaucoma in monkey. We then extended our study to
include another popular glaucoma animal model and to test
whether elevated albumin can be observed in the glaucoma-
tous eyes in rats. Three rats with ocular hypertension for two
weeks were donated for the study. Intraocular pressure was
FIGURE 1. Identification of a 70 kDa protein overexpressed in the
retina of monkeys with experimental glaucoma. Total protein dye
(Deep Purple; GE Healthcare)-stained gel of retinal proteins from the
control (C) and glaucoma (G) eye of the same monkey (OHT 46;
inferior 40°–45°) separated by SDS-PAGE. Although equal amounts of
proteins (20 g) were loaded in each lane, the protein content near 70
kDa was obviously greater in the glaucoma retina (lane 2) than in the
control retina. This same pattern of labeling is seen in six of the
monkeys studied. Only five to six prominent protein bands were
detected since the amount of protein loaded in each well is 1.5–6
times lower than that in most studies. Filled arrow: increased 70 kDa
protein band; open arrowheads: decreased proteins.
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elevated by laser coagulation and the IOP monitored as de-
scribed previously.33 The average IOP of control eyes was
15.08  0.0949 ( SD) mm Hg, and the average IOP in fellow
ocular hypertensive eyes was 31  2.035 mm Hg. A similar
increase (2.4-fold; log-transformed paired t-test; P  0.0483; SE
of ratio  1.23) in albumin content was found in the three rats
with experimental glaucoma (Fig. 5). Retinal ganglion cell loss
at two weeks is 26%  7%.33,34 Data from the seven monkeys
and three rats with experimental glaucoma strongly suggest
that elevation of albumin in retina may be a general response
that is caused by the death of retinal ganglion cells initiated by
high intraocular pressure.
FIGURE 2. Separation of the 70 kDa
protein by two-dimensional PAGE.
Retinal protein extract from monkey
OHT 46 was separated by 2-D–SDS-
PAGE and stained (Deep Purple; GE
Healthcare). The spots correspond-
ing to the abundant 70 kDa protein
indicated by the oval were excised,
destained, and subjected to proteo-
lytic digestion for determination of
amino acid sequences by LC/MS/MS
analysis.
FIGURE 3. Identification of the 70
kDa protein as albumin by MS/MS
analysis and MASCOT search. (A)
The amino acid sequence of serum
albumin (Macaca mulatta) is shown
at the top with bold regions indicat-
ing the eight tryptic peptides identi-
fied by LC/MS/MS analysis. The eight
peptides are a part of the amino acid
sequence of serum albumin. (B) An
example spectrum of the peptide
LVNEVTEFAK is shown. The spec-
trum shown in this example was ob-
tained by LC/MS/MS analysis of the
doubly charged [M  2H] ion.
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Relationship between Albumin Level and Severity
of Glaucoma
The obvious variation in the level of albumin among the seven
experimental monkeys (0.5–2.7-fold increase; Fig. 4) indicated
a possible correlation between the magnitude of albumin ele-
vation and the severity of glaucoma damage or duration of
glaucoma. Comparison of elevated albumin to duration of glau-
coma showed no clear correlation (Table 1). However, exam-
ination of the data in Table 1 suggested a positive correlation
with glaucoma severity. The perimetric mean deviation (MD),
which is an average of visual sensitivity loss across test loca-
tions, provides a global measure of visual deficits that is com-
monly used as an indicator of the severity of glaucoma (Table
1). Regression analysis was performed to determine whether a
correlation is found between albumin abundance and glau-
coma severity or duration of glaucoma. The difference in mean
deviation between the control and glaucoma eye for each
monkey was plotted against the difference in density of nor-
malized albumin labeling between the two eyes of each mon-
key (Fig. 6). The linear regression analysis indicates that albu-
min density increases 0.106 ( 0.2014) units above the control
eye (P  0.0006) for each unit of increase in mean deviation
(R2  0.9198). However, no correlation was found between
duration of glaucoma and the abundance of albumin by linear
regression analysis (R2  0.0067). The lack of correlation
between duration and retinal pathology in glaucomatous mon-
key retinas is consistent with our previous findings.27 These
analyses further confirmed a positive association between the
MD and increased albumin content and, even with the small
sample, strongly imply that albumin content in the retina
increases with the severity of glaucomatous damage and not
with duration.
Localization of Albumin in Retina
Immunohistochemistry was used to identify the retinal local-
ization of increased albumin. Sections of monkey retina, from
the inferior temporal retina between 40° and 45° from the
fovea of control and glaucoma eyes, were immunolabeled with
the monoclonal anti-albumin antibody, stained with DAPI and
examined by confocal microscopy. In control retinas, albumin
was localized predominately to blood vessels (Fig. 7A). No
labeling for albumin was detected in retinal neurons or glia. In
contrast, the glaucomatous retinas (Fig. 7B) contained a high
level of albumin immunoreactivity in some neurons of the
inner nuclear and the inner plexiform layers, and along the
vitreal surface.
DISCUSSION
Using two independent methods, proteomic analysis and West-
ern blot, we have demonstrated that albumin is an abundant
protein in the retinas of glaucomatous monkey eyes. The av-
erage albumin content is increased approximately 2.3-fold in
the glaucomatous retinas when compared to retinas of fellow-
eye controls. Further, a similar increase in albumin content is
found in the three retinas of glaucomatous rat eyes. We dem-
onstrated by immunohistochemistry that in addition to the
typical location of albumin in blood vessels, albumin is also
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FIGURE 4. Confirmation that albu-
min is elevated in the retina of mon-
keys with experimental glaucoma by
Western Blot analysis. Equal amounts
of retinal protein extracts from con-
trol and glaucoma monkey eyes were
separated by SDS-PAGE, transferred
to nitrocellulose membranes, and
probed with an antibody to human
serum albumin. Each pair of blots
contains sample from the control
(first lane) and glaucoma eye (sec-
ond lane) of the same monkey for
each of seven monkeys. (A) Labeling
for albumin is apparently greater in
the retina of the glaucoma eye com-
pared with the companion control
eye. (B) Quantitative analysis of the
relative change of albumin in the ret-
ina of glaucoma eyes to that of the
fellow control eye for each monkey,
after normalizing to -actin, show in-
creased amounts of albumin in all but
one of the glaucoma eyes compared
with control eyes.
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found at abnormally high levels outside of blood vessels in
glaucomatous retinas. Albumin is found localized to some neu-
ronal cell bodies of the inner nuclear layer and within cell
processes, as indicated by positive immunolabeling for albu-
min in the inner plexiform layer in glaucomatous eyes. These
results suggest that elevation of albumin may be a general
consequence in the pathophysiology of glaucoma.
Some of the intravascular albumin is redistributed into the
anterior and posterior chambers and the vitreous of the eye via
the ciliary body and iris root.35 In extraocular tissues, albumin
has many functions which include maintenance of osmotic
pressure, transport of hormones, fatty acids, bilirubin, binding
to toxins and metal ions rendering them inactive, along with
antioxidant properties.36 In vitreous, albumin is the dominant
protein, and although its functions in the eye are not yet fully
characterized, it likely serves many of the same functions as it
does in other body tissues.
There is evidence indicating that oxidative injury contrib-
utes to retinal damage in glaucoma.37 In rats with experimental
glaucoma, oxidized proteins have been detected in the retina
by Western blot analysis and are localized predominately to the
inner retina.22 Evidence of oxidative damage also has been
shown in retinas of human patients with glaucoma.37 The
present investigations have demonstrated that albumin levels
are increased in the retina of monkeys with experimental
glaucoma, and it appears to be localized to the same retinal
regions reported to exhibit oxidative damage in eyes of rats
and humans with glaucoma.20,37 The intracellular increase of
albumin in the retinas of monkey eyes with experimental
glaucoma also may occur in response to increased oxidative
injury.
Several studies have supported a role for albumin in neuro-
nal protection and recovery from oxidative insults.38 After
transient ischemia in rats, several studies showed that intrave-
nous serum albumin treatment reduced histologic damage,
enhanced behavioral recovery,39 and improved vascular dy-
namics.40 Based on the positive findings in the rat model of
stroke, clinical trials were initiated and are currently in Phase
III to evaluate the efficacy of albumin as part of the treatment
strategy for stroke patients.41 Albumin treatments also enhance
functional recovery of rats with experimental spinal cord in-
jury.42 The neuroprotective effects of albumin may be exerted
directly on neurons in the models of stroke and spinal cord
injury since in vitro studies show that the excitotoxic effects of
glutamate on spinal cord neurons is reduced when treated with
albumin,42 and it protects cortical neurons,43 as well as non-
neuronal cells such as pancreatic  cells from hydrogen per-
oxide-induced cell death.44 In our laboratory, preliminary stud-
ies show that albumin protects RGC-5 (immortalized retinal
ganglion cells) against cell death induced by oxidative insult
(RR, LCD, XCZ, unpublished observation, 2008). Together,
these studies indicate that albumin contributes to the protec-
tion of cells experiencing oxidative injury. These studies sug-
gest that the presence of extravascular albumin in the inner
retina of eyes with glaucoma may assist in protecting retinal
neurons against oxidative damage.
Extravasated albumin can be translocated intracellularly.
For example, albumin is taken up by cell bodies and dendrites
of neurons in the brain after transient ischemia.45,46 Lens
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FIGURE 5. Increased albumin content is observed in the retina of OHT
rat eyes. (A) Equal amounts of retinal protein extracts from control
(lanes 1, 3, and 5) and from OHT (lanes 2, 4, and 6) eyes were probed
with an antibody directed against rat albumin (rabbit anti-rat albumin;
RAL-25A, 1:5000; Immunology Consultants Laboratory Inc., Newberg,
OR). Albumin content appears greater in the retinas from OHT eyes
compared with their fellow control eyes. (B) Quantitative analysis of
the relative albumin content (normalized to -actin) between the eyes
of the three rats clearly shows more albumin in the retina of OHT eyes.
TABLE 1. Monkey Subjects: Mean Deviation and Duration
Monkey
Mean Deviation (dB)
Duration
(mo)Control Glaucoma
OHT-34 0.00 20.22 2
OHT-47 2.45 8.85 11
OHT-46 0.24 9.91 2
OHT-48 0.19 10.06 14
OHT-51 2.82 8.56 9
OHT-40 2.48 2.39 2
OHT-45 2.62 3.30 5
y = 0.106x - 0.0308
R² = 0.9198
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FIGURE 6. Increase in albumin is positively correlated to the severity
of visual field defect. Scatterplot of the differences in immunolabeling
densities of albumin and the differences in the mean deviation (indi-
cator of severity) reveals a positive association (R2  0.9198) between
the severity of visual field defect and increased albumin immunolabel-
ing density.
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epithelial cells also take up albumin after in vivo injection into
the anterior chamber of rat eyes and it plays a role in the
transport of long chain fatty acids into the lens epithelium47,48
for subsequent incorporation into numerous lipids. It is possi-
ble that albumin, along with fatty acids, is translocated into
cells experiencing oxidative injury in glaucoma and that the
amount of albumin taken up is relative to the degree of injury.
The increased abundance of albumin in the retina of glau-
comatous eyes is likely derived from one or more of these
sources: (1) retinal vasculature, (2) vitreous, or (3) de novo
synthesis within retina. Normally, as with the brain, there is a
blood–retina barrier that is established by the retinal pigment
epithelium and the tight junctions formed between the endo-
thelial cells lining the lumen of retinal vessels. Typically, albu-
min and other proteins or hormones destined for the extravas-
cular space must be transported across the endothelium.
Enhanced transport, or a breakdown in the blood–retina bar-
rier, would result in an increase in extravascular albumin. An
increase in vascular permeability has been reported to occur in
the optic nerve head of patients with open-angle glaucoma.49
Several other studies have reported evidence of vascular anom-
alies leading to reduced vascular perfusion of the retina and the
optic nerve in patients with glaucoma, which can lead to
hypoxia. Hypoxia in human glaucoma is supported by the
presence of increased immunoreactivity for hypoxia-inducible
factor  (HIF-1) in the inner retina, blood vessels, and optic
nerve compared with age-matched controls.50 Hypoxia can
lead to disruption of the endothelial barrier function in neural
vasculature.51 The presence of increased albumin in the retinas
of the monkeys and rats with experimental glaucoma may be
the result of a breakdown of the blood–retinal barrier; how-
ever, entry of albumin from the vitreous or de novo synthesis
in response to oxidative stress similar to that reported in an in
vitro model of cornea wound healing52 cannot be eliminated.
Additional studies will be necessary to establish the source of
the increased intracellular albumin in the retinas of monkeys
with experimental glaucoma.
In conclusion, this study shows that albumin is increased in
the retinas of monkeys with experimental glaucoma. The in-
crease in albumin is localized predominately to the same region
of inner retina and to neurons that typically exhibit increased
oxidative damage in glaucoma. Our findings also show that the
amount of retinal albumin is positively correlated with severity
of glaucoma damage. Because albumin is a major antioxidant in
the body, the increased intracellular albumin in the glaucoma-
tous retina may contribute to the antioxidant activity of injured
neurons. The protective effect against oxidants provided by
albumin maybe insufficient to save the RGCs, but sufficient for
protecting cells in the inner nuclear layer.
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